WeVote
Log In

Bill

Bill

SB 3005

Relating to a study on the use of psychedelic therapies in the treatment of certain conditions.

89th Legislature (2025) Introduced by César Blanco and 3 co-sponsors

Texas would fund a study on psychedelic therapy's effectiveness for treating specific medical conditions without legalizing the substances.

Co-author authorized
#baylorcollegeofmedicine(u0250) #dellmedicalschoolattheuniversityoftexasataustin(u0239) #health--otherdiseases&medicalconditions(i0383) #insurance--health&accident(i0422) #interimstudies(i0448) #medicine&prescriptiondrugs(s7338) #mentalhealth&substanceabuse(i0019) #statehealthservices #departmentof(v0463)
0
WeVote Research Nonpartisan
Bill Summary · SB 3005

Legislative bill overview

SB 3005 directs the state of Texas to conduct a comprehensive study on the therapeutic applications of psychedelic substances for treating specific medical and mental health conditions. The bill does not legalize or authorize use of psychedelics but rather mandates research into their potential clinical benefits and establishes a framework for evaluating their efficacy.

Why is this important

As psychedelic-assisted therapy gains traction in clinical research nationally, Texas would join other states examining whether these substances could address treatment-resistant conditions like PTSD, depression, and end-of-life anxiety. The study's findings could inform future policy decisions about regulated medical access and position Texas within an evolving healthcare landscape where federal restrictions may eventually shift.

Potential points of contention

  • Federal-state legal conflict: Psilocybin, LSD, and other psychedelics remain Schedule I controlled substances federally, creating uncertainty about how Texas researchers could legally conduct such studies without federal approval and potential DEA complications.
  • Research methodology concerns: Critics may question whether the study adequately addresses safety protocols, proper clinical controls, and long-term outcome measurements, or whether it represents advocacy disguised as research.
  • Scope ambiguity: The bill's reference to "certain conditions" lacks specificity about which disorders would be studied, potentially allowing broad interpretation or concerns that conditions aren't evidence-based selections.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.